ADMA Biologics Inc (NASDAQ:ADMA) — Market Cap & Net Worth
Market Cap & Net Worth: ADMA Biologics Inc (ADMA)
ADMA Biologics Inc (NASDAQ:ADMA) has a market capitalization of $1.93 Billion ($1.93 Billion) as of September 17, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #6302 globally and #2008 in its home market, demonstrating a -10.50% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ADMA Biologics Inc's stock price $8.61 by its total outstanding shares 223984680 (223.98 Million). Also see ADMA Biologics Inc total assets for a full breakdown of the balance sheet.
ADMA Biologics Inc Market Cap History: 2015 to 2026
ADMA Biologics Inc's market capitalization history from 2015 to 2026. Data shows change from $1.81 Billion to $1.93 Billion (-1.23% CAGR). Also see ADMA Biologics Inc cash flow conversion for how efficiently the company converts equity into cash flow.
Index Memberships
ADMA Biologics Inc is a constituent of 4 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.66 Trillion | 0.07% | #179 of 976 |
|
NASDAQ Composite
IXIC
|
$41.74 Trillion | 0.00% | #717 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.88 Trillion | 0.10% | #108 of 263 |
|
S&P Small-Cap 600 Index
SML
|
$1.61 Trillion | 0.39% | #332 of 602 |
Weight: ADMA Biologics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
ADMA Biologics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ADMA Biologics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check ADMA Biologics Inc share price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
8.01x
ADMA Biologics Inc's market cap is 8.01 times its annual revenue
Latest Price to Earnings (P/E) Ratio
27.81x
ADMA Biologics Inc's market cap is 27.81 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.15 Billion | $10.66 Million | -$19.52 Million | 107.57x | N/A |
| 2017 | $718.99 Million | $22.76 Million | -$43.76 Million | 31.59x | N/A |
| 2018 | $535.32 Million | $16.99 Million | -$65.74 Million | 31.52x | N/A |
| 2019 | $895.94 Million | $29.35 Million | -$48.28 Million | 30.53x | N/A |
| 2020 | $436.77 Million | $42.22 Million | -$75.75 Million | 10.35x | N/A |
| 2021 | $315.82 Million | $80.94 Million | -$71.65 Million | 3.90x | N/A |
| 2022 | $869.06 Million | $154.08 Million | -$65.90 Million | 5.64x | N/A |
| 2023 | $1.01 Billion | $258.21 Million | -$28.24 Million | 3.92x | N/A |
| 2024 | $3.84 Billion | $426.45 Million | $197.67 Million | 9.01x | 19.43x |
| 2025 | $4.09 Billion | $510.17 Million | $146.93 Million | 8.01x | 27.81x |
Competitor Companies of ADMA by Market Capitalization
Companies near ADMA Biologics Inc in the global market cap rankings as of September 17, 2026. Review ADMA Biologics Inc (ADMA) tangible equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to ADMA Biologics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #186 globally with a market cap of $130.44 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.29 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.82 Billion USD ( AU$84.54 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #506 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #186 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.44 Billion | $514.63 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.29 Billion | $774.11 |
| #457 | CSL Ltd | AU:CSL | $59.82 Billion | AU$174.26 |
| #506 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $143.77 |
ADMA Biologics Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, ADMA Biologics Inc's market cap moved from $1.81 Billion to $ 1.93 Billion, with a yearly change of -1.23%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.93 Billion | -52.80% |
| 2025 | $4.09 Billion | +6.36% |
| 2024 | $3.84 Billion | +279.42% |
| 2023 | $1.01 Billion | +16.49% |
| 2022 | $869.06 Million | +175.18% |
| 2021 | $315.82 Million | -27.69% |
| 2020 | $436.77 Million | -51.25% |
| 2019 | $895.94 Million | +67.36% |
| 2018 | $535.32 Million | -25.55% |
| 2017 | $718.99 Million | -37.30% |
| 2016 | $1.15 Billion | -36.56% |
| 2015 | $1.81 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of ADMA Biologics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.93 Billion USD |
| MoneyControl | $1.93 Billion USD |
| MarketWatch | $1.93 Billion USD |
| marketcap.company | $1.93 Billion USD |
| Reuters | $1.93 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About ADMA Biologics Inc
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indic… Read more